Peter leads the firm’s asset development and financing division including RTW’s company creation efforts. His team incubates and builds businesses around the most innovative science identified by the firm.
Peter also serves as founding CEO of these new companies, building their management teams, pipelines, and drug development capabilities with the goal of creating the next generation of leading biotech firms capable of bringing life-saving medicines to patients. He serves on the board of directors for both Ji Xing Pharmaceuticals and Yarrow Biotechnologies, both of which were founded by RTW under his leadership. In addition to his role as head of company creation, Peter also leads RTW’s asset development and financing team and its management of RTW’s corporate finance, business development, and transaction legal responsibilities.
Prior to joining RTW, Peter worked at Flagship Pioneering in Cambridge as a member of the innovation team. In this role he led the creation of four Flagship companies, including Harbinger Health, and served as iCEO of each of them.
Biotech entrepreneurism is central to the unprecedented biological innovation revolutionizing medicine. It’s a thrill to come to the office each day and work with colleagues as talented and entrepreneurial as they are at RTW. Together, we seek to create world class biotech companies – from the ground up – capable of taking on the worst diseases.
Peter previously worked at Genentech in Business Development, where he helped build the company’s pipeline through partnering. Peter led multiple key transactions for Genentech, including the company’s collaboration with BioNTech to develop mRNA-based personalized cancer vaccines. He has also worked at Memorial Sloan-Kettering; Carigent Therapeutics, which he co-founded; and General Electric as a chemist.
Peter received a PhD in bioengineering from Yale University, where he subsequently was a Brown-Coxe Postdoctoral Fellow, and his BS in biochemistry from Indiana University.